“I will never give up!”

Nobel laureate Robert Koch (1843 – 1910)
German physician and microbiologist,
discovered the Tuberculosis pathogen in 1882.

In Memoriam

We remember a friend and a collaborator we will miss dearly: Johannes Newrkla, whom we all knew as “Jani”.

 

 

With his competence and creativity, Jani created the logo and the corporate image of Austrianni—an image that conveys the mission and the spirit of our Company and its founding members. With his unique ability to listen, share a goal and desire to help achieving this goal, Jani was truly interested in our work and kept following our progress. Most notably, for the re-launch of Austrianni’s website, he spent time in our labs in order to understand how we generate and characterise a therapeutic antibody. Just like with exploring other fields new to him, Jani deeply enjoyed his lab experience.

 

Jani was charismatic, yet humble and friendly. We remember the smile, the generosity, and the remarkable creativity.

 

We miss you, Jani

Who We Are

Austrianni GmbH is a pharmaceutical company with the mission to develop therapeutics for the prevention and treatment of tuberculosis.

Technologies

Our technologies

We’ll do whatever it takes to generate new drugs for tuberculosis therapy. These drugs are either chemicals or biologicals, e.g., antibiotics or human antibodies. Traditionally, the discovery of either one of these medicines has required large teams, but recently, dedicated contract research organizations have taken over important parts of the processes. This allows us to concentrate on our core competencies that we have assembled in our company.

Antibodies

Austrianni has unrestricted access to the powerful antibody discovery platform developed by the California company Trianni. This platform features the complete diversity of human antibody variable domains, which undergo natural V(D)J recombination and somatic hyper-mutation. Using this platform, Austrianni isolates fully human antibody therapeutics for the treatment of tuberculosis, with emphasis on multidrug resistant tuberculosis.

Small Molecules.

There are many enzymes that Myco-bacterium tuberculosis cannot live without, and several antibiotics exploit this fact. Traditionally, antibiotics were found by testing large collections of microorganisms, or large collections of chemicals, for their ability to interfere with bacterial growth. Or chemical libraries were tested against an isolated target. In either case, only a tiny fraction of the vast chemical space of drug-like structures, estimated to consist of 1063 structures, can be covered.

Antibodies

Austrianni has unrestricted access to the powerful antibody discovery platform developed by the California company Trianni. This platform features the complete diversity of human anti-body variable domains, which undergo natural V(D)J recombination and somatic hyper-mutation. Using this platform, Austrianni isolates fully human antibody therapeutics for the treatment of tuberculosis, with emphasis on multidrug resistant tuberculosis.

Partners

News

Upcoming events

Members of the Austrianni team take part in conferences dedicated to the investigation of the host-pathogen relationship in TB, and in other conferences that deal with the biotech, pharma and healthcare business. In the following, some of these upcoming events are listed.

IMPRINT

CONTACT

CAREER

© 2019 AUSTRIANNI. All rights reserved.